Optimizing outcomes in schizophrenia: Long-acting depots and long-term treatment

CNS Spectrums

Volumn 17, Issue SUPPL.1, 2012, Pages 10-21

  Morrissette, Debbi A ^a   Stahl, Stephen M ^a,b  

^a NEUROSCIENCE EDUCATION INSTITUTE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; CLOZAPINE; HALOPERIDOL; LURASIDONE; NEUROLEPTIC AGENT; OLANZAPINE; PLACEBO; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

AKATHISIA; ARTICLE; BRIEF PSYCHIATRIC RATING SCALE; CAUSE OF DEATH; CLINICAL GLOBAL IMPRESSION SCALE; COST BENEFIT ANALYSIS; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; EXTRAPYRAMIDAL SYNDROME; HUMAN; LONG TERM CARE; MONTGOMERY ASBERG DEPRESSION RATING SCALE; PARKINSONISM; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; QUALITY OF LIFE; SCHIZOPHRENIA; TARDIVE DYSKINESIA; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT REFUSAL;

ADULT; ANTIPSYCHOTIC AGENTS; BRAIN; DELAYED-ACTION PREPARATIONS; DRUG SUBSTITUTION; HUMANS; LONG-TERM CARE; MEDICATION ADHERENCE; PSYCHIATRIC STATUS RATING SCALES; PSYCHOTIC DISORDERS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SURVIVAL ANALYSIS; YOUNG ADULT;

EID: 84871448891     PISSN: 10928529     EISSN: None     Source Type: Journal    
DOI: 10.1017/S1092852912000739     Document Type: Article

References (70)

1. Brundtland GH. From the World Health Organization. Mental health: new understanding, new hope. JAMA. 2001; 286(19): 2391.
2. Mura G, Petretto DR, Bhat KM, Carta MG. Schizophrenia: from epidemiology to rehabilitation. Clin Pract Epidemiol Ment Health. 2012; 8: 52-66.
3. Manschreck TC, Boshes RA. The CATIE schizophrenia trial: results, impact, controversy. Harv Rev Psychiatry. 2007; 15(5): 245-258.
4. Mullins CD, Obeidat NA, Cuffel BJ, Naradzay J, Loebel AD. Risk of discontinuation of atypical antipsychotic agents in the treatment of schizophrenia. Schizophr Res. 2008; 98(1-3): 8-15.
5. Glick ID, Correll CU, Altamura AC, et al. Mid-term and long-term efficacy and effectiveness of antipsychotic medications for schizophrenia: a data-driven, personalized clinical approach. J Clin Psychiatry. 2011; 72(12): 1616-1627.
6. Morrissette DA, Cutler AJ. Strategies for optimizing medication adherence in schizophrenia. CNS Spectrums. 2012; 17(01): 31-41.
7. Mitchell AJ. Adherence behaviour with psychotropic medication is a form of self-medication. Med Hypotheses. 2007; 68(1): 12-21.
8. Mitchell AJ, Selmes T. Why don't patients take their medicine? Reasons and solutions in psychiatry. Advances in Psychiatric Treatment. 2007; 13(5): 336-346.
9. Freudenreich O, Tranulis C. A prototype approach toward antipsychotic medication adherence in schizophrenia. Harv Rev Psychiatry. 2009; 17(1): 35-40.
10. Llorca PM. Partial compliance in schizophrenia and the impact on patient outcomes. Psychiatry Res. 2008; 161(2): 235-247.
11. Robinson D, Woerner MG, Alvir JM, et al. Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Arch Gen Psychiatry. 1999; 56(3): 241-247.
12. Caseiro O, Perez-Iglesias R, Mata I, et al. Predicting relapse after a first episode of non-affective psychosis: a three-year follow-up study. J Psychiatr Res. 2012; 46(8): 1099-1105.
13. Ucok A, Polat A, Cakir S, Genc A. One year outcome in first episode schizophrenia. Predictors of relapse. Eur Arch Psychiatry Clin Neurosci. 2006; 256(1): 37-43.
14. Subotnik KL, Nuechterlein KH, Ventura J, et al. Risperidone nonadherence and return of positive symptoms in the early course of schizophrenia. Am J Psychiatry. 2011; 168(3): 286-292.
15. Weiden PJ, Kozma C, Grogg A, Locklear J. Partial compliance and risk of rehospitalization among California Medicaid patients with schizophrenia. Psychiatr Serv. 2004; 55(8): 886-891.
16. Leucht S, Tardy M, Komossa K, Heres S, Kissling W, Davis JM. Maintenance treatment with antipsychotic drugs for schizophrenia. Cochrane Database Syst Rev. 2012; 5: CD008016.
17. Leucht S, Tardy M, Komossa K, et al. Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis. Lancet. 2012; 379(9831): 2063-2071.
18. Tiihonen J, Lonnqvist J, Wahlbeck K, et al. 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study). Lancet. 2009; 374(9690): 620-627.
19. Alvarez-Jimenez M, Gleeson JF, Henry LP, et al. Prediction of a single psychotic episode: a 7.5-year, prospective study in first-episode psychosis. Schizophr Res. 2011; 125(2-3): 236-246.
20. Harrow M, Jobe TH, Faull RN. Do all schizophrenia patients need antipsychotic treatment continuously throughout their lifetime? A 20-year longitudinal study. Psychol Med. 2012: 1-11.
21. Dell'osso B, Glick ID, Baldwin DS, Altamura AC. Can Long-Term Outcomes Be Improved by Shortening the Duration of Untreated Illness in Psychiatric Disorders A Conceptual Framework. Psychopathology. 2012.
22. Stahl SM, Cucchiaro J, Simonelli D, Hsu J, Pikalov A, Loebel A. Long-term safety and tolerability of lurasidone for patients with schizophrenia following 6 weeks of acute treatment with lurasidone, olanzapine, or placebo: a 6-month open-label extension study. Journal of Clinical Psychiatry. 2012; In Press.
23. Addington DE, Labelle A, Kulkarni J, Johnson G, Loebel A, Mandel FS. A comparison of ziprasidone and risperidone in the long-term treatment of schizophrenia: a 44-week, double-blind, continuation study. Can J Psychiatry. 2009; 54(1): 46-54.
24. Hirsch SR, Kissling W, Bauml J, Power A, O'Connor R. A 28-week comparison of ziprasidone and haloperidol in outpatients with stable schizophrenia. J Clin Psychiatry. 2002; 63(6): 516-523.
25. Emsley R, Rabinowitz J, Medori R. Time course for antipsychotic treatment response in first-episode schizophrenia. Am J Psychiatry. 2006; 163(4): 743-745.
26. Lieberman JA, Kane JM, Safferman AZ, et al. Predictors of response to clozapine. J Clin Psychiatry. 1994; 55(Suppl B): 126-128.
27. Schulte P. What is an adequate trial with clozapine?: therapeutic drug monitoring and time to response in treatment-refractory schizophrenia. Clin Pharmacokinet. 2003; 42(7): 607-618.
28. Meltzer HY, Burnett S, Bastani B, Ramirez LF. Effects of six months of clozapine treatment on the quality of life of chronic schizophrenic patients. Hosp Community Psychiatry. 1990; 41(8): 892-897.
29. Rosenheck R, Evans D, Herz L, et al. How long to wait for a response to clozapine: a comparison of time course of response to clozapine and conventional antipsychotic medication in refractory schizophrenia. Schizophr Bull. 1999; 25(4): 709-719.
30. Covell NH, McEvoy JP, Schooler NR, et al. Effectiveness of switching from long-acting injectable fluphenazine or haloperidol decanoate to long-acting injectable risperidone microspheres: an open-label, randomized controlled trial. J Clin Psychiatry. 2012; 73(5): 669-675.
31. Essock SM, Covell NH, Davis SM, Stroup TS, Rosenheck RA, Lieberman JA. Effectiveness of switching antipsychotic medications. Am J Psychiatry. 2006; 163(12): 2090-2095.
32. Rosenheck RA, Davis S, Covell N, et al. Does switching to a new antipsychotic improve outcomes? Data from the CATIE Trial. Schizophr Res. 2009; 107(1): 22-29.
33. Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005; 353(12): 1209-1223.
34. Potkin SG, Weiden PJ, Loebel AD, Warrington LE, Watsky EJ, Siu CO. Remission in schizophrenia: 196-week, double-blind treatment with ziprasidone vs. haloperidol. Int J Neuropsychopharmacol. 2009; 12(9): 1233-1248.
35. Stahl SM, Malla A, Newcomer JW, et al. A post hoc analysis of negative symptoms and psychosocial function in patients with schizophrenia: a 40-week randomized, double-blind study of ziprasidone versus haloperidol followed by a 3-year double-blind extension trial. J Clin Psychopharmacol. 2010; 30(4): 425-430.
36. Lieberman JA, Tollefson G, Tohen M, et al. Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol. Am J Psychiatry. 2003; 160(8): 1396-1404.
37. Marder SR, Glynn SM, Wirshing WC, et al. Maintenance treatment of schizophrenia with risperidone or haloperidol: 2-year outcomes. Am J Psychiatry. 2003; 160(8): 1405-1412.
38. Addington DE, Pantelis C, Dineen M, Benattia I, Romano SJ. Efficacy and tolerability of ziprasidone versus risperidone in patients with acute exacerbation of schizophrenia or schizoaffective disorder: an 8-week, double-blind, multicenter trial. J Clin Psychiatry. 2004; 65(12): 1624-1633.
39. Chrzanowski WK, Marcus RN, Torbeyns A, Nyilas M, McQuade RD. Effectiveness of long-term aripiprazole therapy in patients with acutely relapsing or chronic, stable schizophrenia: a 52-week, open-label comparison with olanzapine. Psychopharmacology (Berl). 2006; 189(2): 259-266.
40. Hsieh MH, Lin WW, Chen ST, et al. A 64-week, multicenter, open-label study of aripiprazole effectiveness in the management of patients with schizophrenia or schizoaffective disorder in a general psychiatric outpatient setting. Ann Gen Psychiatry. 2010; 9: 35.
41. Kasper S, Brecher M, Fitton L, Jones AM. Maintenance of long-term efficacy and safety of quetiapine in the open-label treatment of schizophrenia. Int Clin Psychopharmacol. 2004; 19(5): 281-289.
42. Kasper S. Quetiapine is effective against anxiety and depressive symptoms in long-term treatment of patients with schizophrenia. Depress Anxiety. 2004; 20(1): 44-47.
43. Loebel A, Cucchiano J, Xu J, Sarma K, Pikalov A, Kane JM. Effectiveness of lurasidone vs. quetiapine XR for relapse prevention in schizophrenia: a 12-month, double-blind study. Paper presented at: American Psychiatric Association Annual Meeting 2012; Philadelphia, PA.
44. Stahl SM, Bollu VK, K. R, Pikalov A, Hsu J, Loebel A. Switching from olanzapine to lurasidone: results from a 6-month open label extension study. Paper presented at: American Psychiatric Association Annual Meeting 2012; Philadelphia, PA.
45. Kissling W, Heres S, Lloyd K, et al. Direct transition to long-acting risperidone-analysis of long-term efficacy. J Psychopharmacol. 2005; 19(5 Suppl): 15-21.
46. Gopal S, Vijapurkar U, Lim P, Morozova M, Eerdekens M, Hough D. A 52-week open-label study of the safety and tolerability of paliperidone palmitate in patients with schizophrenia. J Psychopharmacol. 2011; 25(5): 685-697.
47. Leucht C, Heres S, Kane JM, Kissling W, Davis JM, Leucht S. Oral versus depot antipsychotic drugs for schizophrenia-a critical systematic review and metaanalysis of randomised long-term trials. Schizophr Res. 2011; 127(1-3): 83-92.
48. Ereshefsky L, Mascarenas CA. Comparison of the effects of different routes of antipsychotic administration on pharmacokinetics and pharmacodynamics. J Clin Psychiatry. 2003; 64(Suppl 16): 18-23.
49. Tiihonen J, Haukka J, Taylor M, Haddad PM, Patel MX, Korhonen P. A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia. Am J Psychiatry. 2011; 168(6): 603-609.
50. Wheeler A, Vanderpyl J, Carswell C, Stojkovic M, Robinson E. One-year treatment continuation in patients prescribed risperidone long-acting injection in New Zealand: a retrospective study. Clin Schizophr Relat Psychoses. 2012; 6(2): 61-68.
51. Gaebel W, Schreiner A, Bergmans P, et al. Relapse prevention in schizophrenia and schizoaffective disorder with risperidone long-acting injectable vs quetiapine: results of a long-term, open-label, randomized clinical trial. Neuropsychopharmacology. 2010; 35(12): 2367-2377.
52. Keks NA, Ingham M, Khan A, Karcher K. Long-acting injectable risperidone v. olanzapine tablets for schizophrenia or schizoaffective disorder. Randomised, controlled, open-label study. Br J Psychiatry. 2007; 191: 131-139.
53. Rosenheck RA, Krystal JH, Lew R, et al. Longacting risperidone and oral antipsychotics in unstable schizophrenia. N Engl J Med. 2011; 364(9): 842-851.
54. Altamura AC, Aguglia E, Bassi M, et al. Rethinking the role of long-acting atypical antipsychotics in the community setting. Int Clin Psychopharmacol. 2012.
55. Carson WH, Perry P, Sanchez R, et al. Effects of longacting injectable formulation of aripiprazole on secondary efficacy outcomesin maintenance treatment of schizophrenia. Paper presented at: American Psychiatric Association Annual Meeting 2012; Philadelphia, PA.
56. Fleischhacker WW, Sanchez R, Perry P, et al. Long-term safety and tolerability of once-monthly aripiprazole-intramuscular-depot for maintenance treatment in schizophrenia. Paper presented at: American Psychiatric Association Annual Meeting 2012; Philadelphia, PA.
57. Kane JM, Sanchez R, Perry P, et al. Efficacy of aripiprazole-intramuscular-depot for the long-term maintenance treatment of schizophrenia. Paper presented at: American Psychiatric Association Annual Meeting 2012; Philadelphia, PA.
58. Kane JM, Sanchez R, Perry PP, et al. Aripiprazole intramuscular depot as maintenance treatment in patients with schizophrenia: a 52-week, multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2012; 73(5): 617-624.
59. Peng X, Ascher-Svanum H, Faries D, et al. Decline in hospitalization risk and health care cost after initiation of depot antipsychotics in the treatment of schizophrenia. Clinicoecon Outcomes Res. 2011; 3: 9-14.
60. Boonstra G, van Haren NE, Schnack HG, et al. Brain volume changes after withdrawal of atypical antipsychotics in patients with first-episode schizophrenia. J Clin Psychopharmacol. 2011; 31(2): 146-153.
61. Ho BC, Andreasen NC, Ziebell S, Pierson R, Magnotta V. Long-term antipsychotic treatment and brain volumes: a longitudinal study of first-episode schizophrenia. Arch Gen Psychiatry. 2011; 68(2): 128-137.
62. Leung M, Cheung C, Yu K, et al. Gray matter in firstepisode schizophrenia before and after antipsychotic drug treatment. Anatomical likelihood estimation metaanalyses with sample size weighting. Schizophr Bull. 2011; 37(1): 199-211.
63. Navari S, Dazzan P. Do antipsychotic drugs affect brain structure? A systematic and critical review of MRI findings. Psychol Med. 2009; 39(11): 1763-1777.
64. Nielsen MO, Rostrup E, Wulff S, et al. Improvement of Brain Reward Abnormalities by Antipsychotic Monotherapy in Schizophrenia. Arch Gen Psychiatry. 2012: 1-10.
65. Shepherd AM, Laurens KR, Matheson SL, Carr VJ, Green MJ. Systematic meta-review and quality assessment of the structural brain alterations in schizophrenia. Neurosci Biobehav Rev. 2012; 36(4): 1342-1356.
66. Li M, Chen Z, Deng W, et al. Volume increases in putamen associated with positive symptom reduction in previously drug-naive schizophrenia after 6 weeks antipsychotic treatment. Psychol Med. 2012; 42(7): 1475-1483.
67. Seeman P. Dopamine D2 receptors as treatment targets in schizophrenia. Clin Schizophr Relat Psychoses. 2010; 4(1): 56-73.
68. Remington G, Mamo D, Labelle A, et al. A PET study evaluating dopamine D2 receptor occupancy for longacting injectable risperidone. Am J Psychiatry. 2006; 163(3): 396-401.
69. Remington G, Kapur S. Antipsychotic dosing: how much but also how often? Schizophr Bull. 2010; 36(5): 900-903.
70. Bushe C, Taylor M, Haukka J. Mortality in schizophrenia. J Psychopharmacol. 2012; 26(9): 1285.